|Alzforum Home Active Topics Email Notify Search Help Register Login|
|Alzforum Bulletin Boards : Desperately Seeking : Collaborators|
|Topic: Requests Prior to March 2007( Topic Closed)|
| Topic: Requests Prior to March 2007
Posted: 08 Mar 2007 at 4:33pm
PLEASE NOTE: To reply to any of the postings to this Topic, "Requests Prior to March 2007," please contact:
Seeking Collaborators—Posted 3 January 2007
ExonHit Therapeutics is a world-leading biotech company in the field of alternative RNA splicing, a process which when deregulated plays a key role in various diseases. We have a special interest in some identified splicing variants differentially implicated in APP processing. We are interested in mapping the expression profile of such splicing variants during aging and Alzheimer disease.
We are seeking collaboration with a laboratory having easy access to brain biopsies of Alzheimer patients and normal, undemented, age-matched control individuals, which would be interested in a collaborative work for publication purpose.
The overall aim of this study is to study and document both the expression profile in various parts of the brain (by Western blot and immunohistochemistry using our available variant-specific antibodies) and the function on APP processing of such splicing variants during aging and Alzheimer disease.—Dr. Laurent Desire, Director NeurologySeeking Collaborators—Posted 10 March 2006
Although Alzheimer's disease (AD) has now become one of the biggest public health issues in the first world, its definitive diagnosis still depends on the postmortem observation of neurofibrillary tangles (NFTs), which correlate in density and localization with the progression of clinical symptoms. The mechanism of NFT formation in AD is not clear. But since they are composed of aggregates of hyperphosphorylated tau protein, the search for AD-specific tau kinases has been a subject of intense study. Tau kinases may indeed be the molecular integrators of various signaling pathways, and characterization of AD-specific kinase activities may elucidate the mechanisms involved in AD-associated factors such as age, oxidative stress, increased amyloid production, and cell cycle activation. Furthermore, identification of tau kinases involved in AD pathology will yield drug targets for combating this disease.
Recently, our two research groups in the Karolinska Institute, Stockholm (KI) and the Centro de Biologia Molecular "Severo Ochoa," Madrid (CBMSO) have joined forces to determine the role of a novel kinase cascade in AD pathology. This cascade comprises targets still new to AD pharma-industry such as mTOR and p70 S6 kinase (p70S6K) as well as targets already under intense study, such as glycogen synthase kinase (GSK3). The KI group, headed by Jin-Jing Pei, entered the AD field in 1993 via the field of human brain pathology, while Filip Lim (CBMSO) first began AD research in 1995 as an application for his work with gene transfer in the nervous system. The diverse skills and know-how of the two groups are highly complementary in view of the fact that they have now converged toward a common goal of using genetically manipulated animal and cell models to determine the mechanism of tauopathic neurodegeneration in AD. Between Stockholm and Madrid, we have a wide range of resources and techniques including cDNA expression plasmids for numerous protein kinases, lenti- and herpes- viral vectors, neuronal cell lines and primary cultures, brain slice cultures, transgenic mice, stereotaxic injection, behavioral tests, histological and biochemical analyses, access to human brain banks. We are now looking for industrial partners with an interest in identifying targets for pharmacological intervention for AD therapy (full project details and disclosure agreement on request).—Main investigators: Jin-Jing Pei and Filip LimSeeking Collaborators.—Posted 6 October 2004
Desperately seeking for SH-SY5Y-APP transgenic cells. Who would like to share these cells with us and collaborate on lipid homeostasis and AD?—Gunter Eckert, Ph.D., Web site: http://www.biozentrum.uni-frankfurt.de/Pharmakologie/ Seeking Collaborators.—Posted 12 April 2004
Perlegen Sciences, a leader in pharmacogenomics, is seeking collaborations with companies and research institutes that have conducted large Alzheimer clinical trials that were subsequently discontinued. Using high-speed technology to sequence entire human genomes, Perlegen researchers are analyzing single-nucleotide polymorphisms (SNPs) in thousands of people to identify which SNPs can be used to optimize treatment with today’s drugs, and which can point researchers to the underlying causes of disease to develop tomorrow’s drugs.
Perlegen is currently collaborating with several of the world’s largest pharmaceutical companies to help identify SNP patterns that affect drug responses and to use that knowledge to deliver safer, more effective drugs to consumers. We have a special interest in drugs that failed in clinical trials but which demonstrated a positive effect in a subset of patients.
If you are a clinician, CRO, pharmaceutical or biotech researcher or manager who has participated in such trials for Alzheimer’s, we would like to hear from you. Perlegen is actively looking for Alzheimer’s drug candidates that could benefit from the company’s pharmacogenomics technology. Ideally, these would be drugs for which blood samples were collected for genetic analysis during clinical trials, but for which development later stalled or was discontinued despite showing promise in earlier trials.—Dr. Raquel Izumi, Director of Clinical Development
Desperately seeking donations of unwanted APP transgenic and
littermate control animals.—Posted 19 February 2004
Seeking Collaborators—Posted 24 October 2003
Seeking Collaborators—Posted 19 June 2003
Seeking Collaborators—Posted 1 April 2003
Seeking Collaborators—Posted 24 September 2002
Seeking Collaborators—Posted 22 August 2002
Seeking Collaborators to help develop novel test battery—Posted 8 July 2002
We have been working on some of the issues you mention above. You can see my work at: www.medafile.com, particularly we are working on developing an on-line test. I have also been working on developing a screening test which uses animal naming.
However, you may be more interested in the work at: www.alzheimersscreen.com. They are putting a more standard neuropsychological battery into a computer format.
In any case, your work is definitely related to what we are trying to do. My own interest is implementing Item Response Theory, and I am currently trying to apply data to the analysis of the Mini-mental State Exam, on the web (preliminary version is on medafile.com, with a calculation for the severity of illness based on "time", but the IRT is not running yet). collaboration, or even discussion about our developments.—Wes Ashford
Bulletin Board Jump